Polystyrene microsphere and 5-fluorouracil release from custom-designed wound dressing films by Maryam Mobed-Miremadi et al.
Mobed-Miremadi et al. Progress in Biomaterials 2013, 2:1
http://www.progressbiomaterials.com/content/2/1/1ORIGINAL RESEARCH Open AccessPolystyrene microsphere and 5-fluorouracil
release from custom-designed wound
dressing films
Maryam Mobed-Miremadi1*, Raki Komarla Nagendra2, Sujana Lakshmi Ramachandruni2, Jason James Rook3,
Mallika Keralapura4 and Michel Goedert1Abstract
Custom-designed wound dressing films of chitosan and alginate have been prepared by a casting/solvent
evaporation method for hydrophobic therapeutic agent encapsulation. In this parametric study, the propylene
glycol (PG) and calcium chloride (CaCl2) concentrations were varied for chitosan and alginate films, respectively.
Mechanical and chemical inter-related responses under observations included thickness (th), elasticity (E), tensile
strength (TS), sorption ability (S%) and kinetics of in-vitro drug release, specifically in terms of membrane time to
burst (tB) and duration of release (tR). As shown by results of a one tailed t-test significance testing at the 95%
confidence interval (α = 0.05), alginate films were significantly more elastic (p = 0.003), thinner (p = 0.004) and more
susceptible to osmotic burst (p = 0.011) and characterized by a longer duration of release (p = 0.03). Meanwhile
chitosan films exhibited superior moisture permeability (p = 0.006) and sorption characteristics (p = 0.001), indicative
of higher hydrophilicity. There were no significant differences in tensile strength (p = 0.324) for alginate and
chitosan-based formulations. Preliminary testing was conducted using 0.71 μm in diameter microspheres for
modeling film dissolution into Lactated Ringer’s solution. Experimental release profiles were modeled for each film
from which the average release from alginate films (MAGCa = 81%) was estimated to be twice the percentage
associated with chitosan films (MCD = 42%). The film comprised of 2.5% (w/v) medium MW chitosan/dextran 70 kDa
(5:1) was selected for studying the release of 5-Fluorouracil (5-FU) as a model hydrophobic drug. Diffusion coupled
with film disintegration is immediate (tB = 0) in case of encapsulated 5-FU as compared to the control film
encapsulating microspheres characterized by tB = 70 min ± 7 min. This shift in release profile and the ability to
modulate the timing of membrane burst can be attributed to the approximate ratio (1: 505) in molecular size between
drug and microsphere. This hypothesis has been validated by the film pore size measured to be 430 nm± 88 nm using
atomic force microscopy.
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5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione known as
5-Fluorouracil (5-FU) is a therapeutic agent used to treat
non-melanoma skin, breast, and pancreatic cancer admi-
nistered orally, intravenously (Adrucil) or topically as a
cream (Effudex) (Giannola et al. 2010, 2012; Loven et al.
2002). This agent has a molecular weight of 130 g/mol, is
partially soluble in water with a maximum solubility of* Correspondence: maryam.mobed-miremadi@sjsu.edu
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reproduction in any medium, provided the orig1 mg/ml, and has an LD50 = 230 mg/kg (orally in mice)
(Fluorouracil 2012). As shown by the results of a recent
in vitro study of release of 5-FU from Chitosan-Alginate
microcapsules, minimal drug release has been reported in
the stomach and small intestine. This is an advantage be-
cause 5-FU controlled release is required to avoid the side
effects associated with such agents (Shabbear et al. 2012).
Woolfson et al. reported that a 5-FU bio-adhesive patch
can be used for local delivery to the uterine cervix in the
condition of cervical intraepithelial neoplasia (CIN) which
is common and potentially malignant, affecting women iner. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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cant delay in the absorption of 5-FU through patches due
to the controlled release of drug from the patches. The
half-life was statistically significant (p < 0.01) compared to
intravenous route in rabbits and such half-life is observed
in humans in the conventional route (Diasio & Harris
1989). The enhancement in drug delivery by the transder-
mal patch as compared to intravenous delivery was shown
by results of a clinical evaluation of 5-FU from transder-
mal patches on cell-induced tumors in mice indicating a
statistical increase in survival time of 7 days (p < 0.01)
(Chandrashekar & Prasanth 2008). These patches were
based on an ethylcellulose and polyvinylpyrrolidone K-30
(PVP K-30; ratio: 8:2) formulation, di-butylphthalate as a
plasticizer, and 2% (v/w) of isopropyl myristate as a per-
meation enhancer. In vitro induction of apoptosis and cell
cycle arrest by polyvinylpyrrolidone K-30 has been re-
cently reported (Wang et al. 2003) and isopropyl myristate
is classified as a skin irritant ( 2000).
In parallel it has been extensively documented that the
use of biocompatible and biodegradable alginate and
chitosan wound dressing films/patches are advantageous
in many ways: 1) They kill bacteria and prevent infec-
tions caused by systemic invasion (Burkatovskaya et al.
2008); 2) They promote a better healing environment by
absorbing the wound exudate (Murakami et al. 2010);
3) They eliminate the need for wiping or washing the
wounds in between new dressings (Ayogi et al. 2007);
4) They have good bio-adhesive properties, eliminating
the need for surgical adhesives (Khan et al. 2000). The
three most common means of film drying mentioned in
the above references are air drying, thermostatic, and
freeze drying. Meng et al. found that the films dried in
open air were drier than expected (Meng et al. 2010).
Sezer et al. observed that lyophilizing resulted in thick
films with larger pores (Sezer et al. 2007) and the size
of the pores in the films was found to increase the con-
centration of chitosan, thus improving the ability of
the wound dressing to absorb the wound fluids. In a
more recent study of cross-linked scaffolds for tissue
engineering, for the 4–12% (w/v), no change in pore
size range as a function of chitosan concentration was
observed; but porosity was found to be inversely pro-
portional to the chitosan content (Jana et al. 2012).
In light of the aforementioned findings and the need for
a biocompatible transdermal controlled-release mechan-
ism for hydrophobic therapeutic agents, the specific aim
of this research is to devise formulations for fabricating
chitosan and alginate wound dressings with embedded
fluorescent microspheres mimicking a potential drug to
be encapsulated in these films. The amounts of polymers,
plasticizer, and cross-linking agents used for the film for-
mulations will be varied for this parametric study. The
film will be characterized in terms of thickness, elasticity,tensile strength, sorption, and the kinetics of release will
be empirically modeled to calculate the amount of com-
pound released. Lactated Ringer solution will be used as
simulated body fluid or wound exudate for wet tests. The
ideal film based on the stated criteria will then be chosen
to encapsulate 5-FU and studied in terms of drug release
profile and pore size characterization.
Materials and methods
Materials
The following chemicals were purchased from Sigma-
Aldrich (MO, USA): Medium MW chitosan (44887, 75-
85% deacetylated), Medium MW alginic acid (A2033),
Dextran 70 kDa (31390), propylene glycol (P4347), lactic
acid (L6661), glycerol (G2025), calcium chloride (C5670),
polyethylene glycol (81260), sodium citrate dihydrate
(W302600), glacial acetic acid (320099), 5-Fluorouracil
(858471). Polystyrene microspheres (Catalog No. G700B)
internally- dyed with Fluorescent Green (excitation
468 nm /emission 508 nm) were purchased from Duke
Scientific Corporation (CA, USA) Lactated Ringer’s solu-
tion (Catalog No 6E2323) was purchased from Baxter
(IL, USA).
Methods
The stoichiometric amounts of polymers, plasticizer, and
cross-linking agents used for the film formulations used
in this parametric study are outlined in Table 1.
For the chitosan films (CD) and the alginate films
(AGCa), the plasticizer (propylene glycol, PG) and cross-
linker (calcium chloride, CaCl2) concentrations were var-
ied, respectively. Although the role of cross-linker and
plasticizer differ entirely in formulating composite films,
the variables were chosen to overcome the documented
limitations associated with each biopolymer: addressing
stiffness and lack of porosity for chitosan (Jana et al.
2012; Mobed & Chang 1998; Madsen et al. 2011), and
regulation of the encapsulated compound release rate
for alginate (Shabbear et al. 2012; Simpliciano & Asi
2012). Three films were fabricated for each formulation
and measurements were conducted in triplicate unless
indicated otherwise.
Film fabrication
All films were fabricated by a casting/solvent evapor-
ation technique.
Chitosan films were fabricated based on the modifica-
tion of a previously proposed formulation design, specif-
ically with the removal of corn starch and the cytotoxic
cross-linking agent glutaraldehyde from the formulation
(Wittaya-arrekul & Prasharn 2006). Chitosan, dextran
and 5-FU (0.07% w/v) were dispersed in DI water for
1 hr and PG was then added to this solution. This step
was followed by the addition of lactic acid at a rate of
Table 1 Custom design formulations for chitosan, alginate and control films
Film name Polymer1 Polymer2 Plasticizer Crosslinking Agent Solvent
Chitosan Chitosan (g) Dextran (g) Propylene Glycol (ml) Lactic acid (ml) DI water (ml)
CD 0.0 2.5 0.5 0 3.0 97.0
CD 0.5 2.5 0.5 0.5 3.0 96.5
CD 1.0 2.5 0.5 1.0 3.0 96.0
CD 1.5 2.5 0.5 1.5 3.0 95.5
Alginate Alginate (g) N/A Glycerol (ml) CaCl2 (g) DI water (ml)
AGCa 0.04 2.0 - 0.4 0.04 99.6
AGCa 0.08 2.0 - 0.4 0.08 99.6
AGCa 0.12 2.0 - 0.4 0.12 99.6
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plexes with negatively-charged moieties such as sodium
carboxymethylcellulose, citrates, pectin, acacia, agar, so-
dium caprylate, stearic acid sodium tri-polyphosphate, lac-
tic acid, malic acid, and alginic acid (Tiwary & Rana 2010;
Adusumilli & Bolton 1991; Akbuga & Bergisadi 1996;
Suheyla 1997; Dureja et al. 2001; Wang et al. 2001). Al-
though chitosan solubility is a function of molecular
weight and degree of deacetylation, the reported solubility
threshold for this polyelectrolyte is 4. Lactic acid (pKa =
3.86) at a concentration 0.025 M acts as a solubilizer for
the protonated amine group of the chitosan (Zhao et al.
2009). In this study, a 0.43 M lactic acid solution was used
(3% (v/v) and thus cross-linking occurred by means of
electrostatic interactions. The homogenized mixture was
subsequently stirred to crosslink for 8 hrs. In the case of
fluorescent microspheres (1% v/v), the particles were
dispensed into the chitosan/dextran solution prior to the
cross-linking step and did not undergo the pre-mixing
step as is the case for 5-FU.
Alginate films were fabricated based on a modification
of a previously proposed methodology (Rhim 2004). The
solution was prepared by the gradual addition of alginate
powder over a 1 hr period into a stirred solution of DI
water, glycerol and 5-FU (0.07% w/v). Subsequently,
CaCl2 pellets were added in one shot to cross-link the
solution for 8 hrs. In the case of fluorescent micro-
spheres (1% v/v), the particles were dispensed into the
alginate/glycerol solution prior to the cross-linking step
and did not undergo the pre-mixing step as is the case
for 5-FU.
The stirring speed was set to 240 rpm for the dissol-
ution and cross-linking steps for both chitosan and
alginate films. This speed was chosen to overcome the
gradual thickening of the polymer solutions as a result
of cross-linking.
A 25 ml solution of either alginate or chitosan-based
formulation was poured into a 6.06-cm diameter glass
petri-dish and allowed to degas at 4°C overnight. Subse-
quently, the solvent (DI water) was allowed to evaporateunder ambient conditions (25°C and relative humidity of
55% ± 10%) for 24 hrs. The circular dried patches were
cut using scissors to have an area of approximately
10 cm2 and stored in an air tight container under ambi-
ent conditions for 1 week prior to use.
Thickness measurements
Film thickness (th) was measured using an EPIPHOT Nikon
transmission microscope/camera (Model40) equipped with
the NIS-Elements Basic Research Software imaging soft-
ware. Five points were randomly taken at different loca-
tions of the film.
Tensile testing
The modulus of elasticity (E) of these wound dressings
was estimated using an in-house stress–strain gage con-
sisting of a ScoutPro scale (mg resolution) and an elec-
tronic length measurement device, the limits for which
are 581.4 g and 25.75 mm, respectively. A 0.5 cm2 rect-
angular sample strip was used as test sample. The ends
of films were fastened with glue to the unit, and both
the scale and length measurement device were zeroed.
The knob on the measurement device was then turned
to a displacement of 0.5 mm and both the elongation
and mass were recorded until the film fractured and the
test was completed. Measurements were conducted on
films encapsulating microspheres only. Displacements
were applied and resultant forces were measured. Stress
(σ) is subsequently calculated by dividing force by the
cross-sectional area (A) of the film (Eqn. 1) (Callister &
Rethwisch 2010). The strain ε is calculated by dividing
the film displacement (elongation, ΔL) by the initial
length of the stent (L) (Eqn. 2). The elastic modulus (E)
is then calculated from Eqn. 3, which is the slope of the
linear portion of the stress–strain curve. The tensile
strength (TS) is also found by the stress–strain curve,
which represents the maximum stress the stent can
undergo under tensile stretching before the moment of
necking (Eqn. 4). Tensile strength was taken as the high-
est point (Fmax) of the stress-train curve.














Lactated Ringer’s solution (pH = 6.5) was used to simu-
late the behavior of the wound exudate or the area of
lesion onto which the film might be applied (Rhim
2004). The biopolymer sorption ability was determined
gravimetrically. The weights of strips of completely dried
films were determined directly with a digital balance
(mg resolution) and immersed into Lactated Ringer’s
solution for a 24 hr period. The resultant swollen films
were gently blotted with filter paper to remove excess
surface water and weighed again. The sorption ability of
the film is expressed in terms of percentage of weight
increased using Eqn. 5.




Wb weight of the film before immersing in solution
Wa weight of the film after immersing in solution and
blotting
Drug release testing
At the initial stage, 5-FU release profile was simulated
by the use of 0.71 μm in diameter microspheres that
were mixed into individual formulations and thus em-
bedded in the films to simulate the behavior of a hydro-


























Figure 1 Calibration curves for concentration determination as a funcbeaker simulating a mixing tank containing 100 ml of
Ringer’s Lactate (pH = 6.5). Under these sink conditions,
compound release occurs from all surfaces of the matrix
differing from the geometry of the in-use wound dres-
sing, a methodology pursued in previous studies (Gay
et al. 1983; Tada et al. 2010). Franz cells or diffusion
chambers are used in standard in vitro test for diffusion
experiments for researching transdermal drug adminis-
tration (Franz 1978; Smith & Haigh 1992). As reported,
this type of testing often yields permeation data that suf-
fer from poor reproducibility compounding the method
variation with the sample non-uniformities (Ng et al.
2010; Chilcott et al. 2005). Due to the lack of knowledge
on the topography, porosity, surface roughness of the
films, and the associated variance, it was decided to
proceed with the traditional immersion method (Gay
et al. 1983; Tada et al. 2010). The release and film- dis-
solution profiles were characterized by analyzing the op-
tical density in the supernatant. Samples of 0.5 ml from
the supernatant mixed with 0.5 ml of Ringer’s Lactate
were taken every 5 min and centrifuged at 3,000 g prior
to being subjected to spectrophometric analysis using a
UV–VIS spectrophotometer (Agilent 8453) at wave-
lengths of 555 nm for beads and 279 nm for 5-FU,
respectively. Throughout the UV–VIS spectrum, the
polystyrene beads will scatter light in the Mie domain
(van de Hulst 1981). In addition, the size of the beads is
comparable to that of bacteria for which optical density
characterization due to particle light scattering is con-
ducted in the range of 550–600 nm (Shuler & Kargi
2010) and thus the justification behind the wavelength
of 555 nm for microsphere detection. Linear calibration
curves for converting optical density to concentration
for 5-FU and the beads are presented in Figures 1a and
1b, respectively. In order to create quantitative drug
elution responses, the time release plots were compared
in terms of three time periods: a) Lag phase defined as
the duration of membrane hydration, b) Membrane
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tion of optical density (a) 5-FU, (b) microspheres.
6 cm
Figure 2 Photograph of chitosan and alginate custom design
wound dressing films. Fluorescent microspheres are immobilized in
colored specimens while the (CD0.5) encapsulating 5-FU are colorless.
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Phase defined as the period (dC/dt = 0) during which the
membrane has entirely disintegrated and the encapsulated
substances are free in solution. The burst time (tB) and
release time (tR) are defined as the duration of lag and
burst phases, respectively. The duration of release per for-
mulation as a function of time was also modeled as a func-
tion of concentration (C) and the steady state
concentration (CSS). For all models residuals (SSE) were
minimized using the Solver Tool in Excel 2010.
Pore size measurement
3 cm2 samples were cut from each film by a razor and
glued onto a 15 mm sample disc. This disc was then
placed onto the sample holder and held into place by
two arms, whereupon the sample holder was placed
under the atomic force microscopy (AFM) stage.
Surface imaging was performed on the CD0.5 film
formulations using AFM. The characterization was con-
ducted using an Agilent 5500 AFM using non-contact
mode PPPHR-NC probes (NanoAndMore, USA). Picoview
v1.8 and Gwyddion v2.3 were used as qualitative real-time
and quantitative image analysis software, respectively.
Experimental parameters were set in Picoview that maxi-
mized the trace/retrace profile for optimal imaging. These
parameters were: scan speed of 1 line/s, resolution of 256
pixels, sample scale of 20 microns for surface roughness
measurements, sample scale of 2 microns for pore size
measurements, integral and proportional (I and P) gains of
10, frequency offset at −300 Hz, and stop at percentage at
95%. Four images were obtained at different locations
around the sample. These locations were changed through
the movement of the stage. The average pore size was
obtained by taking the surface profile of the images using
Gwyddion across each film. Average surface roughness
(Ra) was estimated through a statistical algorithm coded
into Gwyddion.
Results
Fabricated circular sample films prepared according to
the formulations in Table 1, are depicted in Figure 2.Table 2 Average results of the parametric study by wound dr
Film name Thickness (μm) [E] (kPa)
CD 0.0 1451 ± 74 58 ± 46
CD 0.5 1431 ± 90 228 ± 40
CD 1.0 1258 ± 68 239 ±30
CD 1.5 901 ± 74 507 ± 80
AGCa 0.04 592 ± 97 1010 ± 246
AGCa 0.08 351 ± 143 1915 ± 220
AGCa 0.12 677 ± 68 2086 ± 400Parametric study
The summary of the parametric study encompassing the
variation in film characteristics as a result of formulation
is presented in Table 2 and Figures 3a-3e.
A one-tailed student t-test was used to compare film
properties as a function of polymer type used (alginate
or chitosan) at the 95% confidence interval (α = 0.05).
Analysis was conducted using the Data Analysis toolbox
of Excel 2010.
Alginate films are characterized by significantly higher
elastic moduli (p = 0.003, ECD = 258 MPa ± 185 MPa .vs.
EAGCa = 1670 MPa ± 578 MPa) and release windows
(p = 0.03, tRCD= 31 min± 5 min .vs. tRAGCa =38 min± 6 min).
A monotonic increase in tensile strength as a function of
plasticizer content (PG) for the CD films and cross-linker
(CaCl2) content for the AGCa films is observed. Chitosan
films exhibit superior sorption characteristics (p = 0.001,
SCD = 1208% ± 233% .vs. SAGCa =306% ± 60.3%), with a
monotonic increase in sorption capability observed as a
function of (PG) content. Chitosan films are also signifi-
cantly thicker (p = 0.004, thCD =1260 μm±255 μm .vs.
thAGCa =540 μm ± 169 μm) as well being resistant to burstessing film
TS (kPa) S (%) tB (min) tR (min)
18 ± 2 962 ± 24 60 ± 3 30 ± 4
39 ± 4 1102 ± 40 70 ± 7 50 ± 2
64 ± 9 1293 ± 62 60 ± 5 25 ± 3
94 ± 11 1474 ± 46 40 ± 6 35 ± 7
27 ± 8 347 ± 24 45 ± 5 55 ± 6
67 ± 7 335 ± 56 30 ± 3 35 ± 1












































































Figure 3 Summary of parametric study for statistically significant film properties by formulation (a) film thickness, (b) elastic Modulus,
(c) percent sorption, (d) lag phase duration,(e) duration of release.
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10 min).
There is no significant difference in tensile strength
(p = 0.324, TSCD = 54 kPa ± 33 kPa .vs. TSAGCa = 67 kPa ±
40 kPa) by main polymer type.
Tensile testing
Elastic modulus and tensile strength were determined
per formulation from the stress strain curves displayed in
Figures 4 and 4b. As mentioned above in average
chitosan-based films are significantly more brittle than
alginate films. Although both chitosan and alginate films
display viscoelastic behaviours, chitosan has linear stress–
strain curves whereas alginate has non-linear curves espe-
cially after 4% strain. Alginate films fractured at much
lower strains (8-10% strain) when compared with chitosan
films (18-38% strain).
Microsphere and drug elution profiles
Averaged release profiles by film formulation (N = 3) are
plotted in Figures 5a and 5b for chitosan and alginatefilms. Corresponding empirical piecewise defined math-
ematical functions modeling the release of encapsulated
compounds [C(t)] using Heaviside functions is given by
Eqn. (6). Release profiles during burst phase as a function
of concentration measurements [R(t)] are presented in
Table 3 for each formulation.
C tð Þ ¼ utB tð ÞR tð Þ  utR tð Þ R tð Þ  Css½  ð6Þ
where
C(t) concentration of encapsulated compound in
solution at anytime
C (t) = 0 t < tB
C(t) = R(t) tB ≤ t < tR
C(t) = CSS t ≥ tR
R(t) concentration of encapsulated compound in
solution during release phase (vol% or mg/ml)
CSS steady state concentration of released compound in
solution (vol% or mg/ml)








































Figure 4 Stress/Strain curves for wound dressings (a) chitosan films, (b) alginate films.
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utB Heaviside function related to tB
utR Heaviside function related to tR
As seen in Figures 5a and 5b, in accordance with the
results of the statistical analysis conducted in the para-
metric study section above by main polymer type, chito-














































Release Time (min) 
5-FU in CD 0.5 Mode
5-FU in CD 0.5
Microsphere in CD 0.5 Mode
Microsphere in CD 0.5
c
Figure 5 Modeled comparative release profiles for (a) encapsulated m
in chitosan films, (c) release of microspheres and 5-FU from CD0.5 filmlonger release times are associated with alginate films.
The values of tB ,tR , Css used are average values per film
and presented in Table 2. The total percentage of micro-
sphere or drug released [M] given by Eqn. 7 can be calcu-
lated by film type from the release profile assuming the
concentration of compound released in the mixing tank is
uniform and the total volume of the Ringer’s solution in
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CD 0.0 microsphere 0.606 ln (t) − 2.4175 0.251 0.00 49
CD 0.5 microsphere 0.4817 ln (t) − 2.016 0.202 0.00 41
CD 0.5 5-FU 0:025 tð Þ0:2
.
0:35þ tð Þ0:2ð Þ 0.013 0.00 57
CD 1.0 microsphere 0.667 ln (t) − 2.774 0.234 0.00 46
CD 1.5 microsphere 0.355 ln (t) − 1.315 0.193 0.00 34
AGCa
0.04
microsphere 0.011 t − 0.530 0.460 0.03 99
AGCa
0.08
microsphere 0.515 ln (t) − 1.157 0.400 0.00 47
AGCa
0.12
microsphere 0:5 t  35ð Þ0:8
.
0:8þ t35ð Þ0:8ð Þ 0.477 0.06 96
ba
Figure 6 Surface roughness determination for the CD 0.5
wound dressing film using atomic force microscopy (a) 2D view
and (b) 3D view of the 20 μm2 scanned area.






R0 tð Þ dt
M0
x 100 x DF ð7Þ
where
M Percentage of encapsulated volume or mass released
M0 Initial volume fraction (ml) or amount (mg) per
100 ml
V Ringer’s solution volume
DF Dilution factor at sampling
The percentage microsphere release ranges were
calculated to be 47-99% and 34%-49% for alginate and
chitosan films, respectively.
Since across all formulations, the elasticity of human
skin rated at 18.8 MPa (Silver et al. 2007) was not sur-
passed, elastic modulus was not a criterion for choosing
the film formulation for studying the release of the
model drug 5-FU. Chitosan, specifically the CD0.5 for-
mulation, was chosen over alginate as the main polymer
to encapsulate 5-FU because of its significantly higher
sorption ability and superior resistance to membrane
burst. Comparative drug elution profiles for the control
CD 0.5 film encapsulating microspheres and 5-FU are
presented in Figure 5c. Drug release was characterized
by the absence of a lag phase (tB = 0) and immediate
diffusion. The percentage of 5-FU released from the
CD0.5 film is 57% as compared to 41% for the CD0.5
film encapsulating the microspheres.
AFM imaging results
Sample 2D and 3D views for surface roughness and pore
size measurements of the CD 0.5 film based on AFM
scans, are presented in Figures 6a-6b and Figures 7a-7b,
respectively. The film is characterized by an average poresize of 430 nm ± 88 nm and roughness of 1.8 nm. AFM
is a technique used for surface characterization and it
can only be hypothesized that the recorded surface
indentations are pores. However, since 5-FU diffuses
through the membrane as proven by the spectrophoto-
metric method and, membrane burst is necessary for the
710 nm microspheres to be released, it is likely that
these features are pores.
Discussion
The viscoelastic behaviors of alginate, chitosan, and al-
ginate/chitosan have been characterized experimentally
as a function of MW, blend composition, degree of sub-
stitution, and extent of cross-linking under compressive
and tensile strains has been characterized by multiple
sources (Storz et al. 2010; Moresi et al. 2001; Mitchell &
Blanshard 1974; Torres et al. 2006; Li et al. 2012; Shon
et al. 2007). As reported in the results section, for algin-
ate films beyond 4% strains, non-linear viscoelasticity
was observed. For non-blended, non-cross linked algin-
ate gels, strains in the range of 3-10% exhibited linear
viscoelastic behavior (Storz et al. 2010). Other studies
showed variation of G’ (storage modulus) on frequency
of oscillation and showed the dependency of viscoelastic
behavior on MW and ratio of mannuronic to glucuronic
groups (Moresi et al. 2001). On average, the experimen-
tal tensile strength is 1000 times lower than values previ-
ously reported for identical formulations (Rhim 2004).
The reported average elongation at break of 10% coin-
cides with the upper limit reported in this study. The
root cause of this discrepancy could reside in the meas-
urement techniques for film thickness. Their results did
not indicate that as the concentration of CaCl2 solution
increased TS increased, which is not well aligned with
the positive correlation observed between the cross-
linker concentration and tensile strength in this study. It
could be inferred that the increase in TS and the decrease
in E by CaCl2 treatment were mainly due to the develop-
ment of cross-linking between carboxyl group of alginate
and Ca2+. Correlations between G’ (storage modulus) and
G” (loss modulus) as a function of concentration and
oscillatory frequency have been reported on rheological
studies conducted on pure chitosan (Torres et al. 2006).
a b
Figure 7 Pore size characterization for the CD 0.5 wound
dressing film using atomic force microscopy (a) 2D view where
dashed circles represent the sample measured pores and
(b) 3D view of the 2 μm2 scanned area.
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tions and at high concentrations of chitosan indicating the
predominance of elastic behavior. G” was higher than G’
at lower concentrations indicating the decrease in elastic
behavior. Their lower limit of chitosan concentration cor-
responds to the nominal 0.025 g/mL used in this study. In
another study, the tensile strength of chitosan films cross-
linked with lactic acid (1.4% w/v in 1% w/v lactic acid), in
absence of dextran and PG, was calculated to be 60 MPa,
approximately 1000 times higher than the average mea-
sured TS for the CD films with an elongation at break of
67% (Khan et al. 2000) as compared to the measured
range of 18-38%. Theoretically, in absence of the plasti-
cizer and a lower chitosan concentration, the reported TS
should have been lower; however, since the thickness of
the films has not been published, it is not possible to
narrow down the cause of this discrepancy.
As quantified by tensile testing measurements, alginate
films were 10 times stiffer than chitosan films with a much
lower fracture strain level. Chitosan is a stiff/rigid polyelec-
trolyte associated with conferring compressive strength to
bio-membranes (Jana et al. 2012; Mobed & Chang 1998).
As for the effect of plasticizer content on the reduction in
thickness of the chitosan films with increase in PG content,
has been reported for other hydrophilic plasticizers such as
polyethylene oxide (PEO). This has been explained by the
contraction of the three-dimensional film matrices due to
strong molecular interactions between chitosan and PEO
molecules (Li et al. 2011). In this study chitosan films are
significantly thicker than alginate films and CD film thick-
ness decreases with increasing PG content. Cited film
thicknesses for chitosan wound dressings range from 0.028
to 0.13 mm (Bhuvaneshwari et al. 2011), approximately 10
times lower than the experimental values. Apart from the
difference in measurement methods, it could be hypothe-
sized that the removal of glutaraldehyde as a chemical
cross-linker substituted by physical cross-linking in lactic
acid, resulted in a less porous matrix, hindering evaporation.
Assuming that the porosity of composite films is regulated
by the amount of plasticizer (Madsen et al. 2011; Li et al.2011), it could be inferred that porosity and hence the rate
of evaporation increases with increasing PG concentrations,
thus resulting in thinner CD films. As indicated by the
results of tensile testing, alginate film cross-linking occurred
and is dependent on cross-linker concentration. Theoretic-
ally, an expected monotonous decrease in film thickness as
a function of degree of cross-linking, and thus higher poros-
ity, should have been recorded. It could be inferred that the
experimental range for the CaCl2 is this study is not large
enough to trigger significant porosity changes.
In this study the chitosan films exhibited significantly
higher hydrophilicity and thus a higher affinity for wound
exudate simulated by the Lactated Ringer’s solution. The
results of the sorption ability of the films indicate a grow-
ing hydrophilicity with an increase in PG concentration
in chitosan films in agreement with previous findings
(Ayogi et al. 2007; Wittaya-arrekul & Prasharn 2006)
identical to the behavior of PEGylated chitosan deriva-
tives (Bhuvaneshwari et al. 2011). The sorption values of
the films are on average 1–5 times higher than the values
previously reported (Wittaya-arrekul & Prasharn 2006)
due to the higher film thicknesses measured in this study.
As the degree of cross-linking increases, alginate water
solubility decreases, resulting in lower sorption capability
of the alginate films (Rhim 2004).
Atomic force microscopy was used in previous studies
looking at the surface roughness and pore size of chitosan
and chitosan alginate composite films (Casettaria et al. 2012;
Dash et al. 2011; Hu et al. 2007; Karakecili et al. 2007; Zheng
et al. 2009; Doulabia et al. 2013). It has been reported that
the surface topography of 100% chitosan had a smooth sur-
face with uniformly distributed short spikes, but when an
additive was introduced, the surface roughness increased
resulting in taller spikes (Doulabia et al. 2013). In these arti-
cles the Ra for several formulations/methods of chitosan film
fabrication ranges from 0.3- to 4.6 nm (Casettaria et al. 2012;
Dash et al. 2011; Hu et al. 2007). The experimental value of
1.8 nm falls within this reported range. The measured pore
sizes of 433 nm±88 nm are larger than the 2.8 -100 nm
previously reported for a scan area of 5 μm2 as compared to
the 2 μm2 adopted in this study (Hu et al. 2007).
It could be inferred that chitosan rigidity, in addition to
thicker-wound dressing walls, are the driving forces behind
the statistically significantly higher average membrane
burst time as compared to alginate films. Even after mem-
brane burst, the average release from alginate films
(MAGCa = 81%) is approximately twice that calculated from
chitosan films (MCD = 42%) from which, it could be in-
ferred that alginate films are more porous than chitosan
films and hence, the justification of using chitosan for
slowing down the release rate of compounds from alginate
membranes (Gaserod et al. 1999; Asthana et al. 2012). The-
oretically, an increase in CaCl2 for the alginate films in
conjunction with an increase in PG content for the
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and hence the diffusion rate (Madsen et al. 2011; Simpli-
ciano & Asi 2012); however, no discernible trends were
observed as a result of varying the aforementioned factors.
These observations are limited by the unknown distribu-
tion of surface-to-through pores for each film obtainable
through scanning electron microscopy.
As previously stated, 5-FU release from the CD 0.5
film was characterized by the absence of a lag phase as
compared to the microsphere release profile from the
same control chitosan-based film. 5-FU has a Stokes ra-
dius of 0.372 nm Fournier (2011) as compared to the
710 nm microsphere. Hence, the absence of lag phase
for the 5-FU release profiles is attributed attributed to
the approximate ratio (1: 505) in molecular size. Given
the film pore size of 430 nm ± 88 nm, membrane burst
due to osmosis is not necessary for drug diffusion while
it is for the larger microspheres. Identical release profiles
as in Figure 5c were generated for the co-encapsulation
of the drug and the microsphere, demonstrating the im-
mediate diffusion of the drug followed by membrane
burst releasing the microspheres (Rook et al. 2012). This
two stage release has been recently documented for the
release of curcumin co-encapsulated with silica micro-
spheres in chitosan scaffolds (Ahmed et al. 2012) al-
though the mechanism of burst has not been elaborated
upon. Revisiting the formulation of the 5-FU film in
order to restore the lag phase into the elution profile
and thus modulate membrane burst time, the drug
should be first encapsulated into microspheres/nanopar-
ticles then immobilized within the wound dressing film,
a successful approach adopted to modulate drug release
and minimize the membrane burst effects (Tada et al.
2010; Ramadas et al. 2000; Dhoot & Wheatley 2003).
Conclusion and future efforts
Composite films of chitosan and alginate, intended for
drug delivery/wound healing applications, were fabri-
cated and characterized. It was revealed by this in-vitro
evaluation that alginate films are significantly stiffer.
Meanwhile chitosan films are thicker, more resistant to
osmotic burst and are more hydrophilic as characterized
sorption rates. With the successful elimination of glutar-
aldehyde from the chitosan film formulations, 5-FU was
encapsulated as a model drug into a chitosan film (CD
0.5) comprised of 2.5% (w/v) Medium MW chitosan/
dextran 70 kDa (5:1) using 0.5 and 3% (v/v) of PG and
lactic acid, respectively. The translated microsphere
release profiles modeled using Heaviside functions as
compared to 5-FU release characterized by the absence
of a lag phase, are supported by AFM pore size measure-
ments. Future porosity characterization should encom-
pass scanning electron microscopy (SEM) measurements
to determine the nature and directionality of the poresas well as the distribution of surface-to- through pores.
Also, at a known porosity and nominal film thickness,
fluorescent spatial and temporal concentration gradients
should be measured in order to obtain diffusivity coeffi-
cients for optimization of the desired pharmacokinetic
flux. In-vitro cytotoxicity testing will be added to the
protocol to assess the effect of the glutaraldehyde
removal from the chitosan formulations.
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